Proteon Therapeutics, Inc. (NASDAQ:PRTO) posted its earnings results on Monday. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.11, Bloomberg Earnings reports.

Shares of Proteon Therapeutics (NASDAQ:PRTO) traded down 1.852% during midday trading on Tuesday, reaching $1.325. 25,385 shares of the company traded hands. Proteon Therapeutics has a 1-year low of $1.10 and a 1-year high of $11.45. The stock’s market capitalization is $22.22 million. The stock’s 50-day moving average is $1.37 and its 200-day moving average is $1.57.

PRTO has been the subject of several recent research reports. Zacks Investment Research lowered shares of Proteon Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Maxim Group set a $6.00 target price on shares of Proteon Therapeutics and gave the company a “buy” rating in a report on Thursday, May 4th. Finally, HC Wainwright set a $3.00 target price on shares of Proteon Therapeutics and gave the company a “hold” rating in a report on Saturday, May 13th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $8.14.

ILLEGAL ACTIVITY WARNING: “Proteon Therapeutics, Inc. (NASDAQ:PRTO) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

Earnings History for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with's FREE daily email newsletter.